









Markets
/
Stocks
/
nasdaq-cosm
/

Cosmos Health Inc

COSM

0.953USD

+0.021+2.30%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

28.33MMarket Cap

LossP/E TTM



Cosmos Health Inc

0.953

+0.021+2.30%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

120 / 175

Overall Ranking

454 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

3.000

Target Price

+511.87%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Cosmos Health Inc. is a global healthcare company. The Company owns a portfolio of pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary, Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It distributes a line of pharmaceuticals and Para pharmaceuticals, including branded generics and over the counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It is also engaged in the research and development (R&D) of patented nutraceuticals and specialized root extracts as well as in the R&D of complex generics and OTC products. It offers Cloudscreen, a multimodal platform specialized in drug repurposing, a process of uncovering new target proteins. It is also specialized in the storage and distribution of pharmaceutical and Para pharmaceutical goods.

Growing

The company is in a growing phase, with the latest annual income totaling USD 54.43M.

Undervalued

The company’s latest PE is -0.92, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 11.57M shares, increasing 18.35% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 134.83K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.15.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.85, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 14.75M, representing a year-over-year increase of 11.65%, while its net profit experienced a year-over-year increase of 9.16%.

Score

Industry at a Glance

Previous score

6.85

Change



Financials

7.87

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.93

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.02

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.12

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.90, which is -53.92% below the recent high of -0.41 and 33.15% above the recent low of -0.60.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 120/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78. The average price target for Cosmos Health Inc is 3.00, with a high of 3.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.32, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 1.15 and the support level at 0.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.32

Change

0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.039

Buy

RSI(14)

61.783

Neutral

STOCH(KDJ)(9,3,3)

75.744

Neutral

ATR(14)

0.104

High Vlolatility

CCI(14)

72.426

Neutral

Williams %R

22.011

Buy

TRIX(12,20)

0.451

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

0.932

Buy

MA10

0.848

Buy

MA20

0.812

Buy

MA50

0.762

Buy

MA100

0.604

Buy

MA200

0.597

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 40.24%, representing a quarter-over-quarter increase of 7.09%. The largest institutional shareholder is The Vanguard, holding a total of 134.83K shares, representing 0.45% of shares outstanding, with 23.01% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Siokas (Grigorios)

6.16M

-0.00%

Bovopoulos (Andreas D)

1.88M

Terzis (Georgios)

727.26K

BlackRock Institutional Trust Company, N.A.

267.80K

Geode Capital Management, L.L.C.

194.12K

+0.35%

The Vanguard Group, Inc.

Star Investors

134.83K

UBS Financial Services, Inc.

61.67K

-13.76%

Bardakis (Nikolaos)

45.00K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.12, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 4.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.